Published in J Biol Chem on February 04, 2000
ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol (1998) 3.06
Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell (2008) 2.71
ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol (2001) 2.60
Integrative analysis of RUNX1 downstream pathways and target genes. BMC Genomics (2008) 2.14
Adaptively inferring human transcriptional subnetworks. Mol Syst Biol (2006) 1.81
Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol Cell Biol (2001) 1.46
Deletion of Mtg16, a target of t(16;21), alters hematopoietic progenitor cell proliferation and lineage allocation. Mol Cell Biol (2008) 1.29
Runx1 deletion or dominant inhibition reduces Cebpa transcription via conserved promoter and distal enhancer sites to favor monopoiesis over granulopoiesis. Blood (2012) 1.22
Genome-wide analysis of the homeobox C6 transcriptional network in prostate cancer. Cancer Res (2008) 1.19
AML1/RUNX1 phosphorylation by cyclin-dependent kinases regulates the degradation of AML1/RUNX1 by the anaphase-promoting complex. Mol Cell Biol (2006) 1.18
Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival. Blood (2008) 1.16
Cell cycle and developmental control of hematopoiesis by Runx1. J Cell Physiol (2009) 1.16
The human cytomegalovirus UL82 gene product (pp71) accelerates progression through the G1 phase of the cell cycle. J Virol (2003) 1.14
The hematopoietic transcription factor AML1 (RUNX1) is negatively regulated by the cell cycle protein cyclin D3. Mol Cell Biol (2005) 1.08
The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes. J Cell Sci (2008) 1.06
Runx1 loss minimally impacts long-term hematopoietic stem cells. PLoS One (2011) 1.06
The human SWI/SNF complex associates with RUNX1 to control transcription of hematopoietic target genes. J Cell Physiol (2010) 1.01
Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation. Blood (2007) 0.99
TGF-β superfamily gene expression and induction of the Runx1 transcription factor in adult neurogenic regions after brain injury. PLoS One (2013) 0.97
A new gene selection procedure based on the covariance distance. Bioinformatics (2009) 0.96
Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein. Mol Cell Biol (2002) 0.96
Runx-dependent expression of PKC is critical for cell survival in the sea urchin embryo. BMC Biol (2005) 0.94
Phosphorylation of RUNX1 by cyclin-dependent kinase reduces direct interaction with HDAC1 and HDAC3. J Biol Chem (2010) 0.92
'Runxs and regulations' of sensory and motor neuron subtype differentiation: implications for hematopoietic development. Blood Cells Mol Dis (2009) 0.81
ETV6/RUNX1 abrogates mitotic checkpoint function and targets its key player MAD2L1. Oncogene (2010) 0.79
Tyrosyl phosphorylation toggles a Runx1 switch. Genes Dev (2012) 0.78
Roles of p15Ink4b and p16Ink4a in myeloid differentiation and RUNX1-ETO-associated acute myeloid leukemia. Leuk Res (2007) 0.77
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (1999) 83.27
Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell (1997) 12.41
AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell (1996) 9.74
Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev (1993) 7.40
Acute myeloid leukemia. N Engl J Med (1999) 7.04
TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia (2003) 4.17
Cell cycle regulation of the E2F transcription factor involves an interaction with cyclin A. Cell (1991) 3.98
Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (1995) 3.38
Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol (1993) 3.17
A role for the adenovirus inducible E2F transcription factor in a proliferation dependent signal transduction pathway. EMBO J (1990) 3.07
ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol (1998) 3.06
The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol (1995) 2.70
ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol (2001) 2.60
Expression at the cell surface of biologically active fusion and hemagglutinin/neuraminidase proteins of the paramyxovirus simian virus 5 from cloned cDNA. Proc Natl Acad Sci U S A (1985) 2.56
TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia (1995) 2.54
Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res (1993) 2.43
CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol Cell Biol (1996) 2.42
YACs and the C. elegans genome. Bioessays (1991) 2.33
Runt homology domain proteins in osteoblast differentiation: AML3/CBFA1 is a major component of a bone-specific complex. J Cell Biochem (1997) 2.27
Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia (2009) 2.24
A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential. Cell (1988) 2.14
Identification of a nuclear matrix targeting signal in the leukemia and bone-related AML/CBF-alpha transcription factors. Proc Natl Acad Sci U S A (1997) 2.06
Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias. Leukemia (2007) 2.04
The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. Mol Cell Biol (1998) 1.98
Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. Leukemia (2009) 1.92
Hemagglutinin-neuraminidase protein of the paramyxovirus simian virus 5: nucleotide sequence of the mRNA predicts an N-terminal membrane anchor. J Virol (1985) 1.87
A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J Biol Chem (2000) 1.84
Non-Hodgkin's lymphoma in childhood. N Engl J Med (1996) 1.83
Acute lymphoblastic leukemia in a developing country: preliminary results of a nonrandomized clinical trial in El Salvador. J Pediatr Hematol Oncol (2000) 1.83
Functional domains of the t(8;21) fusion protein, AML-1/ETO. Oncogene (1995) 1.83
The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene (1995) 1.78
The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol (1996) 1.75
Structural features of the colony-stimulating factor 1 receptor that affect its association with phosphatidylinositol 3-kinase. EMBO J (1990) 1.72
Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions. Leukemia (2009) 1.70
Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1. Mol Cell Biol (1998) 1.69
Different roles of individual N-linked oligosaccharide chains in folding, assembly, and transport of the simian virus 5 hemagglutinin-neuraminidase. Mol Cell Biol (1990) 1.66
A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain. Mol Cell Biol (1995) 1.59
A point mutation at tyrosine-809 in the human colony-stimulating factor 1 receptor impairs mitogenesis without abrogating tyrosine kinase activity, association with phosphatidylinositol 3-kinase, or induction of c-fos and junB genes. Proc Natl Acad Sci U S A (1990) 1.58
The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein. Mol Cell Biol (1998) 1.58
Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol (2004) 1.57
Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein. Mol Cell Biol (1999) 1.53
Identification and predicted sequence of a previously unrecognized small hydrophobic protein, SH, of the paramyxovirus simian virus 5. J Virol (1985) 1.53
Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation. Gene (2000) 1.52
Oncogenic homeodomain transcription factor E2A-Pbx1 activates a novel WNT gene in pre-B acute lymphoblastoid leukemia. Proc Natl Acad Sci U S A (1999) 1.48
Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1. Oncogene (1994) 1.40
Mammalian runt-domain proteins and their roles in hematopoiesis, osteogenesis, and leukemia. J Cell Biochem (1999) 1.40
AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia. Oncogene (1996) 1.36
MN1 overexpression is an important step in the development of inv(16) AML. Leukemia (2007) 1.35
The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein. Mol Cell Biol (2000) 1.33
Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial. Leukemia (2009) 1.33
Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood (1996) 1.32
Luteinizing hormone receptors and testosterone synthesis in two distinct populations of Leydig cells. Endocrinology (1980) 1.32
Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis. Proc Natl Acad Sci U S A (1996) 1.28
Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1. Oncogene (2001) 1.25
TEL, a putative tumor suppressor, modulates cell growth and cell morphology of ras-transformed cells while repressing the transcription of stromelysin-1. Mol Cell Biol (2000) 1.24
An AML-1 consensus sequence binds an osteoblast-specific complex and transcriptionally activates the osteocalcin gene. Proc Natl Acad Sci U S A (1996) 1.21
PCTAIRE-1 and PCTAIRE-3, two members of a novel cdc2/CDC28-related protein kinase gene family. Oncogene (1992) 1.19
11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol (1994) 1.16
The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor. Proc Natl Acad Sci U S A (1999) 1.16
Indirect and direct disruption of transcriptional regulation in cancer: E2F and AML-1. Crit Rev Eukaryot Gene Expr (1995) 1.13
Alterations of the AML1 transcription factor in human leukemia. Semin Cell Dev Biol (2000) 1.12
Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. Cancer Res (1993) 1.11
Ligand-induced phosphorylation of the colony-stimulating factor 1 receptor can occur through an intermolecular reaction that triggers receptor down modulation. Mol Cell Biol (1990) 1.11
RUNX1 associates with histone deacetylases and SUV39H1 to repress transcription. Oncogene (2006) 1.11
E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis. Mol Cell Biol (1997) 1.09
Nucleotide sequence of RNA segment 7 of influenza B/Singapore/222/79: maintenance of a second large open reading frame. Virology (1986) 1.09
IDH1 and IDH2 mutations in pediatric acute leukemia. Leukemia (2011) 1.08
TEL contacts multiple co-repressors and specifically associates with histone deacetylase-3. Oncogene (2001) 1.07
Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia (2009) 1.07
11q23 rearrangements in acute leukemia. Leukemia (1996) 1.07
Molecular cloning, expression pattern, and chromosomal localization of human CDKN2D/INK4d, an inhibitor of cyclin D-dependent kinases. Genomics (1995) 1.05
Extraction of cellular DNA from human cells and tissues fixed in ethanol. Anal Biochem (1987) 1.05
TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J Clin Oncol (1997) 1.04
Transcriptional regulation during myelopoiesis. Mol Biol Rep (1997) 1.04